Denintuzumab

• CAT Number: I042253
• CAS Number: 1630074-14-4
• Purity: ≥95%

Denintuzumab (Cat No.: I042253) is a humanized monoclonal antibody directed against CD19, a surface antigen expressed on B cells and many B-cell malignancies. It is commonly developed as an antibody-drug conjugate (ADC), where the antibody is linked to a cytotoxic agent to deliver targeted cell killing. Denintuzumab binds specifically to CD19-expressing cells, making it a promising therapeutic candidate for conditions like acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma. It is utilized in oncology research to explore targeted therapies for B-cell-driven hematologic cancers.

Reference

[1]. Farhadfar N, et al. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia. Leuk Res. 2016 Oct;49:13-21.
[Content Brief]